“Bimekizumab Efficacy and Safety Through 3 Years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II Trials and Their Open-Label Extension BE HEARD EXT”, J of Skin, vol. 10, no. 2, p. s762, Mar. 2026, doi: 10.25251/g776yf41.